Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases. The company develops BMS-986497 (ORM-6151), which is in phase 1 clinical trial to treat acuta myeloid leukemia and high-risk myelodysplastic syndromes; ORM-1153, which is in preclinical trial to treat acuta myeloid leukemia and heme-onc; and ORM-1023, which is in preclinical trial for the treatment of small cell lung cancer and neuroendocrine tumor. It also develops multiple programs; and E3 Ligase-DAC adaptor. The company was founded in 2016 and is headquartered in Daejeon, South Korea.
Metrics to compare | 475830 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship475830PeersSector | |
|---|---|---|---|---|
P/E Ratio | −64.7x | −40.9x | −0.4x | |
PEG Ratio | 0.24 | −1.13 | 0.00 | |
Price/Book | 16.4x | 4.2x | 2.6x | |
Price / LTM Sales | 93,655.4x | 12.6x | 3.1x | |
Upside (Analyst Target) | - | 52.0% | 58.2% | |
Fair Value Upside | Unlock | 7.1% | 8.5% | Unlock |